Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.43 |
| ▸ | CCND1 | P24385 | 5/20 | 0.43 |
| ▸ | CCND3 | P30281 | 5/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | CCND2 | P30279 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355662 | 1.00 | CDK4 (0.43) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL22191106 | 0.90 | ERN1 (0.45) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL22200708 | 0.90 | ERN1 (0.47) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL29356368 | 0.90 | ERN1 (0.47) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL22200434 | 0.86 | ERN1 (0.41) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL29356047 | 0.86 | ERN1 (0.41) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL22190873 | 0.86 | ERN1 (0.47) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL29353260 | 0.84 | ERN1 (0.51) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL22200548 | 0.84 | ERN1 (0.51) | CDK4CCND1CCND3CDK6ERN1 | |
| SCHEMBL22200542 | 0.83 | ERN1 (0.46) | CDK4CCND1ERN1MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| CN-113508115-A | Pyridopyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme I (IRE I A) for the treatment of cancer diseases | 基因泰克公司 | 2021-10-15 | — | — | CN | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | CDK4 36/4885CCND1 1637/4885CCND3 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.